March 28, 2024
Combining the bispecific antibody amivantamab (Rybrevant) with chemotherapy in the first- or second-line setting offers ongoing benefit to patients with epidermal growth factor receptor (EGFR)–mutated advanced […]
March 28, 2024
TOPLINE: Receipt of the bivalent COVID-19 vaccine was not associated with an increased stroke risk in the first 6 weeks after vaccination with either the Pfizer […]
March 27, 2024
Blood-based screening for colorectal cancer (CRC), also known as a “liquid biopsy,” may be better than nothing among patients who skip established screening tests, but it […]
March 27, 2024
The US Food and Drug Administration (FDA) has approved sotatercept (Winrevair, Merck), for the treatment of adults with pulmonary arterial hypertension (PAH), World Health Organization (WHO) […]
March 27, 2024
The US Food and Drug Administration (FDA) warned consumers in a statement issued on March 26 to avoid certain unapproved over-the-counter topical analgesic products because of […]
March 27, 2024
TOPLINE: Most studies of desiccated thyroid extract (DTE) in treating hypothyroidism are poorly designed, and the quality of evidence is low. Non-randomised studies tend to show […]
March 27, 2024
The investigational bispecific T-cell engager tarlatamab achieved durable responses and clinically meaningful survival outcomes in patients with small-cell lung cancer (SCLC), particularly at lower doses, according […]
March 27, 2024
(Reuters) -Novocure’s therapy met the main goal of a late-stage trial of slowing the progression of cancer to the brain in patients with a type of […]
March 27, 2024
TOPLINE: The inclusion of sugar-substitute sweeteners and sweetness enhancers in a sugar-reduced maintenance diet following weight loss improves weight maintenance as well as well-being in adults, […]
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488
Next page